ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALPN Alpine Immune Sciences Inc

64.97
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Alpine Immune Sciences Inc NASDAQ:ALPN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 64.97 68.23 61.74 0 01:00:00

Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm

11/04/2024 9:27pm

PR Newswire (US)


Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart


From Mar 2024 to May 2024

Click Here for more Alpine Immune Sciences Charts.

NEW YORK, April 11, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 

Kuehn Law, PLLC (PRNewsfoto/Kuehn Law, PLLC)

Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: 

  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN) click to participate

Alpine Immune Sciences, Inc. has agreed to be acquired by Vertex Pharmaceuticals Incorporated. Under the proposed transaction, Alpine shareholders will receive $65.00 per share.

  • JBT Corporation (NYSE: JBT) click to participate

JBT Corporation entered into a merger agreement with Marel hf. Shareholders of Marel will have the option to receive either €3.60 per share in cash, all in JBT common stock for 0.0407 per share, or a combination of cash and JBT for €1.26 in cash and 0.0265 JBT shares.

  • Eliem Therapeutics, Inc. (NASDAQ: ELYM) click to participate

Eliem Therapeutics, Inc. has entered into an agreement to acquire Tenet Medicines Inc., under which Tenet's shareholders will be compensated with new shares representing 15.4% of Eliem's common stock following the transaction's closure.

  • HireRight Holdings Corporation  (NYSE: HRT) click to participate

HireRight Holdings Corporation has agreed to merge with affiliates of General Atlantic, L.P. and Stope Point Capital LLC for $14.35 per share in cash.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.

How to Get Involved:

Kuehn Law is dedicated to safeguarding shareholder interests. Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at justin@kuehn.law or call (833) 672-0814. Kuehn Law covers all case costs and does not charge its investor clients.  Shareholders are advised to act promptly, as legal rights may be time-sensitive.  For additional information, please visit Merger Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kuehn-law-encourages-alpn-jbt-elym-and-hrt-investors-to-contact-law-firm-302114662.html

SOURCE Kuehn Law, PLLC

Copyright 2024 PR Newswire

1 Year Alpine Immune Sciences Chart

1 Year Alpine Immune Sciences Chart

1 Month Alpine Immune Sciences Chart

1 Month Alpine Immune Sciences Chart

Your Recent History